These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8105596)

  • 21. Pharmacotherapeutic interventions for cocaine abuse: present practices and future directions.
    Crosby RD; Halikas JA; Carlson G
    J Addict Dis; 1991; 10(4):13-30. PubMed ID: 1685672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limbic mechanisms of anxiolytics acting on 5-HT receptors.
    Płaźnik A; Kostowski W; Stefański R
    Pol J Pharmacol; 1994; 46(5):473-7. PubMed ID: 7894537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
    Wilde MI; Markham A
    Drugs; 1996 Nov; 52(5):773-94. PubMed ID: 9118822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
    Moulignier A
    Rev Neurol (Paris); 1994; 150(1):3-15. PubMed ID: 7801037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ; Tyers MB
    Pharmacol Ther; 1990; 47(2):181-202. PubMed ID: 2203069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of 5-HT3 receptor antagonists: clinical overview and nursing implications.
    Bremerkamp M
    Clin J Oncol Nurs; 2000; 4(5):201-7. PubMed ID: 11111451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity.
    Alvarez-Guerra M; d'Alché-Birée F; Wolf WA; Vargas F; Dib M; Garay RP
    Psychopharmacology (Berl); 2000 Jan; 147(4):412-7. PubMed ID: 10672635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
    Tyers MB
    Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders.
    Toll L
    Curr Pharm Des; 2013; 19(42):7451-60. PubMed ID: 23448477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.
    Hagan RM; Kilpatrick GJ; Tyers MB
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S68-75. PubMed ID: 7831443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
    Herpfer I; Lieb K
    CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.
    Rossé G; Schaffhauser H
    Curr Top Med Chem; 2010; 10(2):207-21. PubMed ID: 20166958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-HT
    Fakhfouri G; Rahimian R; Dyhrfjeld-Johnsen J; Zirak MR; Beaulieu JM
    Pharmacol Rev; 2019 Jul; 71(3):383-412. PubMed ID: 31243157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 38. 5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.
    de Bruin NM; Kruse CG
    Curr Pharm Des; 2015; 21(26):3739-59. PubMed ID: 26044973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT3 receptors: pharmacologic and therapeutic aspects.
    Gyermek L
    J Clin Pharmacol; 1995 Sep; 35(9):845-55. PubMed ID: 8786244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The world of serotonin and its receptors. Physiopathologic, clinical, and therapeutic aspects].
    Marco Igual M
    Med Clin (Barc); 1993 Jun; 101(4):144-53. PubMed ID: 8355545
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.